|
CH653021A5
(fr)
|
1981-04-24 |
1985-12-13 |
Delalande Sa |
Derives piperidino, piperazino et homopiperazino, n-substitues par un groupe heterocyclique aromatique, leur procede de preparation et composition therapeutique les contenant.
|
|
IL73534A
(en)
|
1983-11-18 |
1990-12-23 |
Riker Laboratories Inc |
1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
WO1990014844A2
(en)
|
1989-06-06 |
1990-12-13 |
Neorx Corporation |
Sugars as cleavable linkers for the delivery and release of agents in native form
|
|
US5650150A
(en)
|
1990-11-09 |
1997-07-22 |
Gillies; Stephen D. |
Recombinant antibody cytokine fusion proteins
|
|
US5389640A
(en)
|
1991-03-01 |
1995-02-14 |
Minnesota Mining And Manufacturing Company |
1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
|
|
CA2137639C
(en)
*
|
1993-12-09 |
1999-01-26 |
Agustin B. L. Davila |
Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivate thereof having anti-tumor activity and use thereof in the therapy of malignant diseases
|
|
EP0894797A4
(en)
|
1997-01-09 |
2001-08-16 |
Terumo Corp |
NEW AMID DERIVATIVES AND INTERMEDIATES ON YOUR SYNTHESIS
|
|
ZA9811162B
(en)
*
|
1997-12-12 |
2000-06-07 |
Genentech Inc |
Treatment with anti-ERBB2 antibodies.
|
|
US20090208418A1
(en)
*
|
2005-04-29 |
2009-08-20 |
Innexus Biotechnology Internaltional Ltd. |
Superantibody synthesis and use in detection, prevention and treatment of disease
|
|
US20020155108A1
(en)
|
1998-05-04 |
2002-10-24 |
Biocrystal, Ltd. |
Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
|
|
SE9902036L
(sv)
|
1999-06-03 |
2000-07-31 |
Jan Folke Wallenius |
Förfarande och anordning för att under färd bestämma friktionen mellan vägbanan och ett fordons hjul
|
|
FI107193B
(fi)
|
1999-06-03 |
2001-06-15 |
Rouvari Oy R |
Mittausanturi
|
|
KR20010106431A
(ko)
|
1999-06-04 |
2001-11-29 |
에드먼드 최청전 |
불침투성 표면을 시험하기 위한 장치 및 그 방법
|
|
US6331539B1
(en)
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
|
US6573273B1
(en)
|
1999-06-10 |
2003-06-03 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
|
US6541485B1
(en)
|
1999-06-10 |
2003-04-01 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
|
US6756382B2
(en)
|
1999-06-10 |
2004-06-29 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
|
WO2001079299A1
(en)
|
2000-04-13 |
2001-10-25 |
The Rockefeller University |
Enhancement of antibody-mediated immune responses
|
|
ATE440618T1
(de)
|
2000-06-22 |
2009-09-15 |
Univ Iowa Res Found |
Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.
|
|
CN1549726A
(zh)
*
|
2000-07-31 |
2004-11-24 |
耶鲁大学 |
先天性免疫系统指导的疫苗
|
|
AU2001297677B2
(en)
|
2000-10-24 |
2007-07-05 |
Immunex Corporation |
Method for dendritic cells based immunotherapy of tumors using combination therapy
|
|
EP1360486A2
(en)
|
2000-12-08 |
2003-11-12 |
3M Innovative Properties Company |
Screening method for identifying compounds that selectively induce interferon alpha
|
|
JP2008531580A
(ja)
*
|
2000-12-08 |
2008-08-14 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答修飾因子の標的化送達のための組成物および方法
|
|
EP1455700A4
(en)
|
2001-11-16 |
2007-02-14 |
3M Innovative Properties Co |
METHODS AND COMPOSITIONS RELATED TO MRI COMPOUNDS AND TO TOLL-TYPE RECEPTOR (TLR) PATHWAYS
|
|
CA2467828C
(en)
|
2001-11-29 |
2011-10-04 |
3M Innovative Properties Company |
Pharmaceutical formulations comprising an immune response modifier
|
|
US6677349B1
(en)
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
|
CA2478047C
(en)
|
2002-03-01 |
2014-01-21 |
Immunomedics, Inc. |
Rs7 antibodies
|
|
WO2004032829A2
(en)
|
2002-08-15 |
2004-04-22 |
3M Innovative Properties Company |
Immunostimulatory compositions and methods of stimulating an immune response
|
|
US20040101909A1
(en)
|
2002-08-20 |
2004-05-27 |
Hema-Quebec, 2535 Boul. Laurier, Ste-Foy, Quebec, Canada G1V 4M3 |
Purification of polyreactive autoantibodies and uses thereof
|
|
US6924154B2
(en)
|
2002-08-20 |
2005-08-02 |
Quest Diagnostics Investments Incorporated |
Hydrophilic chemilumescent acridinium labeling reagents
|
|
JP2006503068A
(ja)
|
2002-09-26 |
2006-01-26 |
スリーエム イノベイティブ プロパティズ カンパニー |
１ｈ−イミダゾダイマー
|
|
WO2004053452A2
(en)
|
2002-12-11 |
2004-06-24 |
3M Innovative Properties Company |
Assays relating to toll-like receptor activity
|
|
AU2003287324A1
(en)
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Gene expression systems and recombinant cell lines
|
|
EP1590348A1
(en)
|
2002-12-20 |
2005-11-02 |
3M Innovative Properties Company |
Aryl / hetaryl substituted imidazoquinolines
|
|
WO2004060319A2
(en)
|
2002-12-30 |
2004-07-22 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
|
US7375180B2
(en)
|
2003-02-13 |
2008-05-20 |
3M Innovative Properties Company |
Methods and compositions related to IRM compounds and Toll-like receptor 8
|
|
US7485432B2
(en)
|
2003-02-27 |
2009-02-03 |
3M Innovative Properties Company |
Selective modulation of TLR-mediated biological activity
|
|
EP1613956A2
(en)
|
2003-03-25 |
2006-01-11 |
3M Innovative Properties Company |
Selective activation of cellular activities mediated through a common toll-like receptor
|
|
US20040265351A1
(en)
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
|
WO2004108072A2
(en)
|
2003-04-10 |
2004-12-16 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds using metal-containing particulate support materials
|
|
AU2004252409A1
(en)
|
2003-04-10 |
2005-01-06 |
3M Innovative Properties Company |
Methods and compositions for enhancing immune response
|
|
WO2004096144A2
(en)
|
2003-04-28 |
2004-11-11 |
3M Innovative Properties Company |
Compositions and methods for induction of opioid receptors
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
MY157827A
(en)
|
2003-06-27 |
2016-07-29 |
3M Innovative Properties Co |
Sulfonamide substituted imidazoquinolines
|
|
WO2005016275A2
(en)
|
2003-08-05 |
2005-02-24 |
3M Innovative Properties Company |
Formulations containing an immune response modifier
|
|
CA2535338C
(en)
|
2003-08-14 |
2013-05-28 |
3M Innovative Properties Company |
Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
|
|
WO2005019429A2
(en)
|
2003-08-22 |
2005-03-03 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for enhancing phagocytosis or phagocyte activity
|
|
CA2536136C
(en)
|
2003-08-27 |
2012-10-30 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted imidazoquinolines
|
|
US20150071948A1
(en)
|
2003-09-26 |
2015-03-12 |
Gregory Alan Lazar |
Novel immunoglobulin variants
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
EP1686992A4
(en)
|
2003-11-25 |
2009-11-04 |
3M Innovative Properties Co |
HYDROXYLAMINE, AND IMIDAZOQUINOLEINS, AND IMIDAZOPYRIDINES AND IMIDAZONAPHTYRIDINE SUBSTITUTED WITH OXIME
|
|
WO2005065678A1
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Immunomodulatory combinations
|
|
US20060018911A1
(en)
|
2004-01-12 |
2006-01-26 |
Dana Ault-Riche |
Design of therapeutics and therapeutics
|
|
TW200612932A
(en)
|
2004-03-24 |
2006-05-01 |
3M Innovative Properties Co |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
|
JP2007532572A
(ja)
|
2004-04-09 |
2007-11-15 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫反応調整剤を送達させるための方法、組成物および調製物
|
|
CN1997382A
(zh)
|
2004-05-05 |
2007-07-11 |
梅里麦克制药股份有限公司 |
调节生物活性的双特异性结合剂
|
|
US8017779B2
(en)
|
2004-06-15 |
2011-09-13 |
3M Innovative Properties Company |
Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
|
AU2005283085B2
(en)
|
2004-06-18 |
2012-06-21 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
|
TR201808537T4
(tr)
|
2004-09-23 |
2018-07-23 |
Genentech Inc |
Sistein değiştirilmiş antikorlar ve konjugatlar.
|
|
EP1809671B1
(en)
|
2004-11-09 |
2014-07-16 |
University Of Southern California |
CpG/antibody conjugate against cancer
|
|
US8435800B2
(en)
|
2004-11-22 |
2013-05-07 |
Biosight Ltd. |
Activated labeling reagents and methods for preparing and using the same
|
|
US20070014795A1
(en)
|
2004-12-30 |
2007-01-18 |
Dhodapkar Madhav V |
Compositions and methods for enhanced dendritic cell maturation and function
|
|
CA2592904C
(en)
|
2004-12-30 |
2015-04-07 |
3M Innovative Properties Company |
Chiral fused [1,2]imidazo[4,5-c] ring compounds
|
|
AU2006210392A1
(en)
|
2005-02-04 |
2006-08-10 |
Coley Pharmaceutical Group, Inc. |
Aqueous gel formulations containing immune response modifiers
|
|
JP2008532933A
(ja)
|
2005-02-11 |
2008-08-21 |
コーリー ファーマシューティカル グループ，インコーポレイテッド |
置換イミダゾキノリン類および置換イミダゾナフチリジン類
|
|
AU2006272497B2
(en)
|
2005-07-27 |
2012-07-19 |
University Of Florida Research Foundation, Inc. |
Small compounds that correct protein misfolding and uses thereof
|
|
US8354249B2
(en)
|
2005-08-11 |
2013-01-15 |
Omrix Biopharmaceuticals Ltd. |
Intravenous immunoglobulin composition
|
|
CN101304748A
(zh)
|
2005-08-22 |
2008-11-12 |
加利福尼亚大学董事会 |
Tlr激动剂
|
|
CA2626556C
(en)
|
2005-10-21 |
2016-05-10 |
Genzyme Corporation |
Antibody-based therapeutics with enhanced adcc activity
|
|
US20080286819A1
(en)
|
2005-11-07 |
2008-11-20 |
Ravetch Jeffrey V |
Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
|
|
US8951528B2
(en)
|
2006-02-22 |
2015-02-10 |
3M Innovative Properties Company |
Immune response modifier conjugates
|
|
WO2007103048A2
(en)
|
2006-03-01 |
2007-09-13 |
Regents Of The University Of Colorado |
Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
|
|
CN101479375B
(zh)
|
2006-05-03 |
2016-03-30 |
科罗拉多州立大学董事会 |
Cd40激动剂抗体/1型干扰素协同佐剂组合、包含前述的结合物及其作为增强细胞免疫的治疗剂的用途
|
|
US20080031887A1
(en)
|
2006-06-30 |
2008-02-07 |
Joseph Lustgarten |
Conjugates for inducing targeted immune responses and methods of making and using same
|
|
JP2009542714A
(ja)
|
2006-06-30 |
2009-12-03 |
ベイラー リサーチ インスティテュート |
ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞
|
|
GB0614098D0
(en)
|
2006-07-15 |
2006-08-23 |
Mnl Pharma Ltd |
Immune response variegation with imino sugars
|
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
|
US20080241139A1
(en)
|
2006-10-31 |
2008-10-02 |
Regents Of The University Of Colorado |
Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
|
|
US20080149123A1
(en)
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
|
EP2129773B1
(en)
|
2007-02-23 |
2013-02-13 |
Baylor Research Institute |
Therapeutic applications of activation of human antigen-presenting cells through dectin-1
|
|
KR20090118981A
(ko)
|
2007-02-23 |
2009-11-18 |
베일러 리서치 인스티튜트 |
Ｃｌｅｃ-6을 통한 사람 항원제시세포의 활성화
|
|
KR101805140B1
(ko)
|
2007-03-01 |
2017-12-05 |
심포젠 에이/에스 |
재조합 항-표피 성장 인자 수용체 항체 조성물
|
|
JP2010530005A
(ja)
|
2007-06-15 |
2010-09-02 |
イミュアールエックス・インコーポレーテッド |
Ｔｎｆ−ｒアゴニスト療法レジメンの毒性を緩和するためのｔｌｒアゴニスト及び／又は１型インターフェロンの使用
|
|
WO2009018500A1
(en)
|
2007-07-31 |
2009-02-05 |
The Johns Hopkins University |
Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
|
|
US20090155289A1
(en)
*
|
2007-11-01 |
2009-06-18 |
Steve Roberts |
Furin-cleavable peptide linkers for drug-ligand conjugates
|
|
US20100098657A1
(en)
|
2007-12-27 |
2010-04-22 |
Schafer Peter H |
Method of Treating Cancer with Immunomodulatory Compounds and IgG
|
|
CA2713137C
(en)
|
2008-01-25 |
2017-10-24 |
Hadasit Medical Research Services And Development Ltd. |
Targeting of innate immune response to tumor site
|
|
BRPI0906309A2
(pt)
|
2008-04-02 |
2020-05-26 |
Macrogenics, Inc |
Imunoglobulina, anticorpo, uso do anticorpo e composição farmacêutica
|
|
KR101764927B1
(ko)
|
2008-04-30 |
2017-08-03 |
이뮤노젠 아이엔씨 |
가교제 및 그 용도
|
|
JP2010032505A
(ja)
|
2008-06-30 |
2010-02-12 |
Arkray Inc |
目的物質の検出方法、それに用いる検出試薬およびその用途
|
|
KR101667319B1
(ko)
|
2008-08-05 |
2016-10-18 |
도레이 카부시키가이샤 |
암의 치료 및 예방용 의약 조성물
|
|
US20100129383A1
(en)
|
2008-10-03 |
2010-05-27 |
The Governors Of The University Of Alberta |
Bifunctional fusion molecules for the delivery of antigens to professional antigen-presenting cells
|
|
US20100150942A1
(en)
|
2008-12-03 |
2010-06-17 |
Cantor Thomas L |
Affinity purified human polyclonal antibodies and methods of making and using them
|
|
WO2010121093A2
(en)
|
2009-04-17 |
2010-10-21 |
Lpath, Inc. |
Humanized antibody compositions and methods for binding lysophosphatidic acid
|
|
WO2010132622A2
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of California |
Anticd20-cpg conjugates and methods of treating b cell malignancies
|
|
RU2016108987A
(ru)
|
2009-08-18 |
2018-11-26 |
Вентиркс Фармасьютикалз, Инк. |
Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
|
|
CN102753542B
(zh)
|
2009-08-18 |
2016-01-20 |
文蒂雷克斯药品公司 |
作为t0ll样受体调节剂的取代的苯并氮杂*
|
|
EP2475391B1
(en)
|
2009-09-09 |
2018-09-12 |
Centrose, LLC |
Extracellular targeted drug conjugates
|
|
CN102597775A
(zh)
|
2009-09-25 |
2012-07-18 |
佐马技术有限公司 |
筛选方法
|
|
GB0917054D0
(en)
|
2009-09-29 |
2009-11-11 |
Cytoguide As |
Agents, uses and methods
|
|
GB0917044D0
(en)
|
2009-09-29 |
2009-11-18 |
Cytoguide As |
Agents, uses and methods
|
|
US8518405B2
(en)
|
2009-10-08 |
2013-08-27 |
The University Of North Carolina At Charlotte |
Tumor specific antibodies and uses therefor
|
|
WO2011096517A1
(ja)
|
2010-02-04 |
2011-08-11 |
東レ株式会社 |
癌の治療及び／又は予防用医薬組成物
|
|
KR101805520B1
(ko)
|
2010-02-04 |
2017-12-07 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방용 의약 조성물
|
|
WO2011096533A1
(ja)
|
2010-02-04 |
2011-08-11 |
東レ株式会社 |
癌の治療及び／又は予防用医薬組成物
|
|
KR101758117B1
(ko)
|
2010-02-04 |
2017-07-14 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방용 의약 조성물
|
|
CN102821788B
(zh)
|
2010-02-04 |
2016-11-16 |
东丽株式会社 |
癌的治疗和/或预防用药物组合物
|
|
US9203872B2
(en)
|
2010-02-19 |
2015-12-01 |
Microsoft Technology Licensing, Llc |
Distributed connectivity policy enforcement with ICE
|
|
GB201003293D0
(en)
|
2010-02-26 |
2010-04-14 |
Adjuvantix Ltd |
Cancer vaccine
|
|
IL323000A
(en)
|
2010-03-05 |
2025-10-01 |
Univ Johns Hopkins |
Compositions and methods for antibodies and fusion proteins targeted for immune modulation
|
|
ES2608475T3
(es)
|
2010-04-13 |
2017-04-11 |
Celldex Therapeutics, Inc. |
Anticuerpos que se unen a cd27 humana y usos de los mismos
|
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
KR20130036246A
(ko)
|
2010-05-07 |
2013-04-11 |
베일러 리서치 인스티튜트 |
사람 ｃｄ8+ ｔ 세포의 수지상 세포 면역수용체(ｄｃｉｒ)-매개 교차프라이밍
|
|
US8841417B2
(en)
|
2010-05-14 |
2014-09-23 |
Abbvie Inc. |
IL-1 binding proteins
|
|
AU2011265054B2
(en)
|
2010-06-08 |
2016-09-15 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
|
WO2011155579A1
(ja)
|
2010-06-10 |
2011-12-15 |
北海道公立大学法人札幌医科大学 |
抗Ｔｒｏｐ－２抗体
|
|
SI2591006T1
(sl)
|
2010-07-09 |
2019-10-30 |
Bioverativ Therapeutics Inc |
Enoverižne molekule, ki jih lahko obdelujemo in polipeptidi izdelani z njihovo uporabo
|
|
PE20130643A1
(es)
|
2010-07-12 |
2013-06-07 |
Covx Technologies Ireland Ltd |
Conjugados de anticuerpos multifuncionales
|
|
AR082686A1
(es)
|
2010-08-13 |
2012-12-26 |
Baylor Res Inst |
Adyuvantes de vacuna que direccionan a los adyuvantes de anticuerpos directamente hacia las celulas presentadoras de antigenos
|
|
NZ608673A
(en)
|
2010-10-01 |
2015-04-24 |
Univ Pennsylvania |
Therapeutic use of a tlr agonist and combination therapy
|
|
US20120321694A1
(en)
|
2010-10-27 |
2012-12-20 |
Daniel Larocque |
Compositions and uses
|
|
EP2638066A4
(en)
|
2010-11-09 |
2015-06-03 |
Medimmune Llc |
ANTIBODY EQUIPMENT FOR HOMOGENEOUS CONJUGATION
|
|
US20120171229A1
(en)
|
2010-12-30 |
2012-07-05 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers with reactive groups that release biologically active agents
|
|
TW201247706A
(en)
|
2011-03-08 |
2012-12-01 |
Baylor Res Inst |
Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
|
|
WO2012135132A1
(en)
|
2011-03-25 |
2012-10-04 |
Baylor Research Institute |
Compositions and methods to immunize against hepatitis c virus
|
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
US8728486B2
(en)
|
2011-05-18 |
2014-05-20 |
University Of Kansas |
Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
|
|
US20140088021A1
(en)
|
2011-05-27 |
2014-03-27 |
Nektar Therapeutics |
Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
|
|
JP6460789B2
(ja)
|
2011-06-03 |
2019-01-30 |
スリーエム イノベイティブ プロパティズ カンパニー |
ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
|
|
JP6415979B2
(ja)
|
2011-06-03 |
2018-10-31 |
スリーエム イノベイティブ プロパティズ カンパニー |
ヒドラジノ１ｈ−イミダゾキノリン−４−アミン及びこれから調製された複合体
|
|
US9534056B2
(en)
|
2011-06-06 |
2017-01-03 |
Immungene Inc |
Engineered TAA antibody-TNFSF member ligand fusion molecules
|
|
HUE033628T2
(en)
|
2011-08-04 |
2017-12-28 |
Toray Industries |
Method for detecting pancreatic cancer
|
|
HUE035689T2
(en)
|
2011-08-04 |
2018-05-28 |
Toray Industries |
A pharmaceutical composition for the treatment and / or prevention of cancer
|
|
CA2844037C
(en)
|
2011-08-04 |
2020-07-14 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
|
|
ES2634249T3
(es)
|
2011-08-04 |
2017-09-27 |
Toray Industries, Inc. |
Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
|
|
DK2740794T3
(en)
|
2011-08-04 |
2018-06-14 |
Toray Industries |
PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR CANCER PREVENTION
|
|
EP2740798B1
(en)
|
2011-08-04 |
2016-12-07 |
Toray Industries, Inc. |
Cancer treatment and/or prevention drug composition
|
|
PT2740795T
(pt)
|
2011-08-04 |
2017-01-09 |
Toray Industries |
Composição de fármaco para o tratamento e/ou a prevenção de cancro
|
|
GB201113570D0
(en)
|
2011-08-05 |
2011-09-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
WO2013025779A1
(en)
|
2011-08-15 |
2013-02-21 |
Amplimmune, Inc. |
Anti-b7-h4 antibodies and their uses
|
|
KR20140066212A
(ko)
|
2011-09-01 |
2014-05-30 |
노파르티스 아게 |
스타필로코쿠스 아우레우스 항원의 보조제 첨가된 조제물
|
|
CN103957939A
(zh)
|
2011-09-19 |
2014-07-30 |
约翰霍普金斯大学 |
癌症免疫治疗
|
|
NL2007536C2
(en)
|
2011-10-05 |
2013-04-08 |
Academisch Ziekenhuis Leiden Lumc |
Adjuvant compound.
|
|
US20130108619A1
(en)
|
2011-11-02 |
2013-05-02 |
Isaac Melamed |
Intravenous immunoglobulin processing, diagnostic, and treatment systems and methods
|
|
CN104661683A
(zh)
|
2011-11-09 |
2015-05-27 |
埃森德生物制药有限公司 |
免疫调节缀合物
|
|
CA2954166A1
(en)
|
2011-11-11 |
2013-05-16 |
Rinat Neuroscience Corp. |
Antibodies specific for trop-2 and their uses
|
|
EP2794653B1
(en)
|
2011-12-23 |
2019-03-13 |
Pfizer Inc |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
US20130323234A1
(en)
|
2012-01-09 |
2013-12-05 |
Covx Technologies Ireland Limited |
Mutant antibodies and conjugation thereof
|
|
WO2013106577A2
(en)
|
2012-01-10 |
2013-07-18 |
Biogen Idec Ma Inc. |
Enhancement of transport of therapeutic molecules across the blood brain barrier
|
|
US20130177574A1
(en)
|
2012-01-11 |
2013-07-11 |
Paul I. Terasaki Foundation Laboratory |
ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
|
|
JP2015512616A
(ja)
|
2012-02-01 |
2015-04-30 |
コンピュゲン エルティーディー． |
Ｃ１ｏｒｆ３２抗体およびがんの治療のためのその使用
|
|
PL2818483T3
(pl)
|
2012-02-21 |
2018-01-31 |
Toray Industries |
Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
|
|
RU2633505C2
(ru)
|
2012-02-21 |
2017-10-12 |
Торэй Индастриз, Инк. |
Фармацевтическая композиция для лечения и/или профилактики рака
|
|
RU2639522C2
(ru)
|
2012-02-21 |
2017-12-21 |
Торэй Индастриз, Инк. |
Фармацевтическая композиция для лечения и/или профилактики рака
|
|
KR102009238B1
(ko)
|
2012-02-21 |
2019-08-09 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방용 의약 조성물
|
|
KR102057356B1
(ko)
|
2012-02-27 |
2019-12-18 |
아뮤닉스 파마슈티컬스, 인크. |
Ｘｔｅｎ 콘주게이트 조성물 및 그의 제조 방법
|
|
CN104220095B
(zh)
|
2012-03-30 |
2016-09-07 |
东丽株式会社 |
肝癌的治疗和/或预防用药物组合物
|
|
DK2832366T3
(en)
|
2012-03-30 |
2018-01-22 |
Toray Industries |
PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF Gallbladder cancer
|
|
CA2870485A1
(en)
|
2012-04-13 |
2013-10-17 |
Whitehead Institute For Biomedical Research |
Sortase-modified vhh domains and uses thereof
|
|
WO2013166110A1
(en)
|
2012-05-02 |
2013-11-07 |
Yale University |
Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms)
|
|
EP2855596B1
(en)
|
2012-05-30 |
2019-02-27 |
Life Technologies Corporation |
FLUOROGENIC pH-SENSITIVE DYES AND THEIR METHODS OF USE
|
|
EP2674170B1
(en)
|
2012-06-15 |
2014-11-19 |
Invivogen |
Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
|
|
UA114108C2
(uk)
|
2012-07-10 |
2017-04-25 |
Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем |
Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
|
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
US20140065096A1
(en)
|
2012-09-05 |
2014-03-06 |
Regen BioPharma, Inc. |
Cancer therapy by ex vivo activated autologous immune cells
|
|
WO2014124316A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
|
EP2787005A1
(en)
|
2013-04-02 |
2014-10-08 |
Activartis Biotech GmbH |
Targeted cancer immune therapy
|
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
|
GB2529356B
(en)
|
2013-04-28 |
2020-12-23 |
Genequantum Healthcare Co Ltd |
Novel linkers, coupling intermediates, conjugates, preparation method and application thereof
|
|
WO2015014376A1
(en)
|
2013-07-31 |
2015-02-05 |
Biontech Ag |
Diagnosis and therapy of cancer involving cancer stem cells
|
|
ES2704909T3
(es)
|
2013-08-09 |
2019-03-20 |
Toray Industries |
Composición farmacéutica para el tratamiento y/o la prevención del cáncer
|
|
CA2934030A1
(en)
|
2013-10-15 |
2015-04-23 |
Sorrento Therapeutics Inc. |
Drug-conjugates with a targeting molecule and two different drugs
|
|
GB201321242D0
(en)
|
2013-12-02 |
2014-01-15 |
Immune Targeting Systems Its Ltd |
Immunogenic compound
|
|
BR112016013963A2
(pt)
|
2013-12-17 |
2017-10-10 |
Genentech Inc |
terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
|
|
JP6841656B2
(ja)
|
2013-12-17 |
2021-03-10 |
ジェネンテック， インコーポレイテッド |
Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用する癌の治療方法
|
|
KR102088169B1
(ko)
|
2013-12-25 |
2020-03-12 |
다이이찌 산쿄 가부시키가이샤 |
항 trop2 항체-약물 컨쥬게이트
|
|
CN104861067A
(zh)
*
|
2014-01-10 |
2015-08-26 |
博笛生物科技有限公司 |
用于免疫疗法的化合物和组合物
|
|
CN104861063A
(zh)
*
|
2014-01-10 |
2015-08-26 |
博笛生物科技有限公司 |
靶向her2阳性肿瘤的化合物和组合物
|
|
SG11201605449YA
(en)
|
2014-01-10 |
2016-08-30 |
Birdie Biopharmaceuticals Inc |
Compounds and compositions for immunotherapy
|
|
WO2015112749A2
(en)
|
2014-01-22 |
2015-07-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
|
|
AU2015233084B2
(en)
|
2014-02-21 |
2020-12-17 |
Anokion Sa |
Glycotargeting therapeutics
|
|
JP6357327B2
(ja)
|
2014-03-11 |
2018-07-11 |
株式会社クレハ |
フッ化ビニリデン系共重合体、その製造方法、ゲル電解質および非水系電池
|
|
EA201691827A1
(ru)
|
2014-03-12 |
2017-01-30 |
Новартис Аг |
Конкретные участки для модификации антител с целью получения иммуноконъюгатов
|
|
EP3129067B1
(en)
|
2014-03-19 |
2023-01-04 |
Genzyme Corporation |
Site-specific glycoengineering of targeting moieties
|
|
CN106459205B
(zh)
|
2014-04-11 |
2021-04-09 |
免疫医疗有限责任公司 |
包含半胱氨酸工程化抗体的轭合化合物
|
|
PL3134402T3
(pl)
|
2014-04-22 |
2020-11-02 |
F.Hoffmann-La Roche Ag |
Związki 4-amino-imidazochinolinowe
|
|
EP3138568B1
(en)
|
2014-04-29 |
2019-04-17 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
New stable antibody-drug conjugate, preparation method therefor, and use thereof
|
|
US20170073415A1
(en)
|
2014-05-12 |
2017-03-16 |
Numab Ag |
Novel multispecific molecules and novel treatment methods based on such multispecific molecules
|
|
US10406198B2
(en)
|
2014-05-23 |
2019-09-10 |
Novartis Ag |
Methods for making conjugates from disulfide-containing proteins
|
|
JP2017525655A
(ja)
|
2014-06-02 |
2017-09-07 |
ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ |
アレルギーおよび炎症性疾患を治療するための方法および組成物
|
|
PL3151921T3
(pl)
|
2014-06-06 |
2020-02-28 |
Bristol-Myers Squibb Company |
Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
|
|
EP4001311B1
(en)
|
2014-07-09 |
2025-11-05 |
Birdie Biopharmaceuticals Inc. |
Anti-pd-l1/pd-1 combinations for treating tumors
|
|
CN112546230A
(zh)
|
2014-07-09 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
US20160015803A1
(en)
|
2014-07-18 |
2016-01-21 |
Ross Kedl |
Immunostimulatory combinations and use thereof
|
|
BR112017001579A2
(pt)
|
2014-07-25 |
2017-11-21 |
Cytomx Therapeutics Inc |
anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
|
|
WO2016028149A1
(en)
|
2014-08-20 |
2016-02-25 |
Tu Eindhoven |
Ureidopyrimidone supramolecular complexes for compound delivery into cells
|
|
JP2017526673A
(ja)
*
|
2014-08-27 |
2017-09-14 |
国立大学法人九州大学 |
アジュバント
|
|
CN112546238A
(zh)
|
2014-09-01 |
2021-03-26 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
|
US9884866B2
(en)
|
2014-09-08 |
2018-02-06 |
Regents Of The University Of Minnesota |
Immunomodulators and immunomodulator conjugates
|
|
AU2015327868A1
(en)
|
2014-10-03 |
2017-04-20 |
Novartis Ag |
Combination therapies
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
US20170304433A1
(en)
|
2014-10-09 |
2017-10-26 |
Wake Forest University Health Sciences |
Vaccine compositions and methods of use to treat neonatal subjects
|
|
GB201418004D0
(en)
|
2014-10-10 |
2014-11-26 |
Isis Innovation |
Polymer adjuvant
|
|
EP3206711B1
(en)
|
2014-10-14 |
2023-05-31 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
EP3209334A2
(en)
|
2014-10-20 |
2017-08-30 |
Igenica Biotherapeutics, Inc. |
Novel antibody-drug conjugates and related compounds, compositions, and methods of use
|
|
WO2016064899A1
(en)
|
2014-10-21 |
2016-04-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
|
|
LT3221363T
(lt)
|
2014-11-21 |
2020-08-10 |
Bristol-Myers Squibb Company |
Antikūnai prieš cd73 ir jų panaudojimas
|
|
US20170266303A1
(en)
|
2014-11-25 |
2017-09-21 |
Endocyte, Inc. |
Methods of treating cancer by targeting tumor-associated macrophages
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
MX393750B
(es)
|
2014-12-31 |
2025-03-24 |
Checkmate Pharmaceuticals Inc |
Inmunoterapia antitumoral combinada.
|
|
AU2016206808A1
(en)
|
2015-01-14 |
2017-08-31 |
Bristol-Myers Squibb Company |
Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
|
|
SG11201705323WA
(en)
|
2015-01-16 |
2017-07-28 |
Academia Sinica |
Molecular constructs with targeting and effector elements
|
|
PL3656443T3
(pl)
|
2015-01-21 |
2022-01-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
Zastosowanie agonisty trl i środka anty-cd47 do wzmocnienia fagotocytozy komórek nowotworowych
|
|
EP3268037B1
(en)
|
2015-03-09 |
2022-08-31 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
WO2016141890A1
(en)
|
2015-03-12 |
2016-09-15 |
Sunshine Lake Pharma Co., Ltd. |
Compounds as hepatitis c virus inhibitors and pharmaceutical uses thereof
|
|
CA2978942A1
(en)
|
2015-03-13 |
2016-09-22 |
Cytomx Therapeutics, Inc. |
Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
|
|
US10584167B2
(en)
|
2015-03-23 |
2020-03-10 |
Bayer Pharma Aktiengesellschaft |
Anti-CEACAM6 antibodies and uses thereof
|
|
WO2016161372A1
(en)
|
2015-04-01 |
2016-10-06 |
President And Fellows Of Harvard College |
Immunoconjugates for programming or reprogramming of cells
|
|
AU2016252771B2
(en)
|
2015-04-22 |
2021-12-16 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
|
|
WO2016179335A1
(en)
|
2015-05-04 |
2016-11-10 |
Cytomx Therapeutics, Inc. |
Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof
|
|
CN107849133B
(zh)
|
2015-05-04 |
2022-08-23 |
西托姆克斯治疗公司 |
抗cd166抗体、可活化抗cd166抗体及其使用方法
|
|
LT3292149T
(lt)
|
2015-05-04 |
2022-03-10 |
Cytomx Therapeutics, Inc. |
Aktyvinami antikūnai prieš cd71 ir jų naudojimo būdai
|
|
US20160324981A1
(en)
|
2015-05-08 |
2016-11-10 |
The California Institute For Biomedical Research |
Liver x receptor agonists and uses thereof
|
|
US10314854B2
(en)
|
2015-05-15 |
2019-06-11 |
University Of Iowa Foundation |
Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
|
|
AU2016264649B2
(en)
|
2015-05-20 |
2018-11-22 |
Immunwork Inc. |
Molecular constructs with targeting and effector elements and their applications
|
|
HK1253082A1
(zh)
|
2015-05-22 |
2019-06-06 |
拉筹伯大学 |
诊断乳腺癌的方法
|
|
PL3303632T5
(pl)
|
2015-05-29 |
2023-07-03 |
F. Hoffmann-La Roche Ag |
Terapeutyczne i diagnostyczne sposoby stosowane w nowotworze
|
|
JP6797137B2
(ja)
|
2015-05-29 |
2020-12-09 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
Ｏｘ４０に対する抗体およびその使用
|
|
EP3302457A2
(en)
|
2015-06-08 |
2018-04-11 |
Lophius Biosciences GmbH |
Composition for determination of cell-mediated immune responsiveness
|
|
CN112125929A
(zh)
|
2015-06-15 |
2020-12-25 |
杭州多禧生物科技有限公司 |
用于偶联的亲水链接体
|
|
WO2016205566A1
(en)
|
2015-06-16 |
2016-12-22 |
The Regents Of The University Of California |
Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
|
|
WO2016205551A2
(en)
|
2015-06-16 |
2016-12-22 |
The Regents Of The University Of California |
Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
|
|
US10975112B2
(en)
|
2015-06-16 |
2021-04-13 |
Hangzhou Dac Biotech Co., Ltd. |
Linkers for conjugation of cell-binding molecules
|
|
EP3310384A1
(en)
|
2015-06-17 |
2018-04-25 |
CureVac AG |
Vaccine composition
|
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
|
JP6700321B2
(ja)
|
2015-07-04 |
2020-05-27 |
ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． |
細胞結合分子の特異的共役体
|
|
AU2015242213A1
(en)
|
2015-07-12 |
2018-03-08 |
Hangzhou Dac Biotech Co., Ltd |
Bridge linkers for conjugation of cell-binding molecules
|
|
JP7014706B2
(ja)
|
2015-07-13 |
2022-02-01 |
サイトメックス セラピューティクス インコーポレイテッド |
抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
CN114272371A
(zh)
|
2015-07-29 |
2022-04-05 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
EP3317301B1
(en)
|
2015-07-29 |
2021-04-07 |
Novartis AG |
Combination therapies comprising antibody molecules to lag-3
|
|
CA2993429A1
(en)
|
2015-07-31 |
2017-02-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immuno-oncology therapies
|
|
AU2016304597B2
(en)
|
2015-08-06 |
2022-10-06 |
Memorial Sloan Kettering Cancer Center |
Methods and compositions for tumor therapy
|
|
TW201716084A
(zh)
|
2015-08-06 |
2017-05-16 |
葛蘭素史克智慧財產發展有限公司 |
組合物及其用途與治療
|
|
CA2991975C
(en)
|
2015-08-10 |
2021-04-06 |
Suzhou M-Conj Biotech Co., Ltd. |
Novel linkers and their uses in specific conjugation of drugs to a biological molecule
|
|
CN107922416B
(zh)
|
2015-08-31 |
2021-07-02 |
3M创新有限公司 |
含有取代的胍基团的咪唑并[4,5-c]环化合物
|
|
WO2017040233A1
(en)
|
2015-08-31 |
2017-03-09 |
3M Innovative Properties Company |
GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS
|
|
US9623118B2
(en)
|
2015-09-01 |
2017-04-18 |
Immunwork Inc. |
Multi-arm linker constructs for treating pathological blood clots
|
|
WO2017044803A1
(en)
|
2015-09-09 |
2017-03-16 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Service |
Expression vector delivery system and use thereof for inducing an immune response
|
|
WO2017046675A1
(en)
|
2015-09-14 |
2017-03-23 |
Pfizer Inc. |
Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
|
|
US20180273948A1
(en)
|
2015-09-25 |
2018-09-27 |
Tarveda Therapeutics, Inc. |
RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF
|
|
CN108770357B
(zh)
|
2015-09-29 |
2022-10-28 |
芝加哥大学 |
聚合物结合疫苗
|
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
|
CN108367011A
(zh)
|
2015-11-02 |
2018-08-03 |
文蒂雷克斯药品公司 |
使用tlr8激动剂治疗癌症
|
|
CA3004830A1
(en)
|
2015-11-11 |
2017-05-18 |
Opi Vi- Ip Holdco Llc |
Composition and methods for anti-tnfr2 antibodies
|
|
WO2017087280A1
(en)
|
2015-11-16 |
2017-05-26 |
Genentech, Inc. |
Methods of treating her2-positive cancer
|
|
TWI703160B
(zh)
|
2015-11-30 |
2020-09-01 |
美商輝瑞股份有限公司 |
用於部位專一性接合之抗體和抗體片段
|
|
KR101795388B1
(ko)
|
2015-12-02 |
2017-11-09 |
현대자동차 주식회사 |
차량용 자동변속기의 유성기어트레인
|
|
EP3386536A4
(en)
|
2015-12-07 |
2019-07-31 |
Opi Vi- IP Holdco LLC |
COMPOSITION OF ANTIBODY CONSTRUCT AGONIST CONJUGATES AND METHOD FOR USE THEREOF
|
|
US20170158772A1
(en)
|
2015-12-07 |
2017-06-08 |
Opi Vi - Ip Holdco Llc |
Compositions of antibody construct - agonist conjugates and methods of use thereof
|
|
ES2986067T3
(es)
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
WO2017117269A1
(en)
|
2015-12-29 |
2017-07-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for dectin-2 stimulation and cancer immunotherapy
|
|
CN106943597A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-egfr组合
|
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
|
CN106943596A
(zh)
|
2016-01-07 |
2017-07-14 |
博笛生物科技（北京）有限公司 |
用于治疗肿瘤的抗-cd20组合
|
|
EP3411074A4
(en)
|
2016-02-04 |
2019-09-04 |
Suzhou M-conj Biotech Co., Ltd. |
SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHOD FOR THE PRODUCTION AND USE THEREOF OF SUCH CONJUGATES
|
|
US11291721B2
(en)
|
2016-03-21 |
2022-04-05 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
US20200078468A1
(en)
|
2016-04-13 |
2020-03-12 |
Tarveda Therapeutics, Inc. |
Neurotensin receptor binding conjugates and formulations thereof
|
|
AU2017252527A1
(en)
|
2016-04-18 |
2018-11-08 |
Celldex Therapeutics, Inc. |
Agonistic antibodies that bind human CD40 and uses thereof
|
|
KR20180134395A
(ko)
|
2016-04-19 |
2018-12-18 |
인네이트 튜머 이뮤니티, 인코포레이티드 |
Nlrp3 조정제
|
|
WO2017184735A1
(en)
|
2016-04-19 |
2017-10-26 |
Ifm Therapeutics, Inc |
Nlrp3 modulators
|
|
CA3021669A1
(en)
|
2016-05-09 |
2017-11-16 |
Igm Biosciences, Inc. |
Anti-pd-l1 antibodies
|
|
WO2017197241A1
(en)
|
2016-05-13 |
2017-11-16 |
Tarveda Therapeutics, Inc. |
Targeted constructs and formulations thereof
|
|
WO2017210246A2
(en)
|
2016-05-31 |
2017-12-07 |
Tarveda Therapeutics, Inc. |
Penicillamine conjugates and particles and formulations thereof
|
|
US12257352B2
(en)
|
2016-06-20 |
2025-03-25 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
WO2018009672A1
(en)
|
2016-07-06 |
2018-01-11 |
University Of Maryland, College Park |
Polyphosphazene polyelectrolytes and uses thereof
|
|
CA3029902A1
(en)
|
2016-07-07 |
2018-01-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antibody adjuvant conjugates
|
|
FI3506884T4
(fi)
|
2016-08-30 |
2024-12-23 |
Dana Farber Cancer Inst Inc |
Lääkkeenantokoostumuksia ja niiden käyttötapoja
|
|
EP3507288B1
(en)
|
2016-09-02 |
2020-08-26 |
Gilead Sciences, Inc. |
4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
|
|
EP3510036B1
(en)
|
2016-09-07 |
2021-07-21 |
GlaxoSmithKline Biologicals SA |
Imidazoquinoline derivatives and their use in therapy
|
|
MY194813A
(en)
|
2016-09-09 |
2022-12-16 |
Novartis Ag |
Compounds and compositions as inhibitors of endosomal toll-like receptors
|
|
EP3532505A4
(en)
|
2016-10-25 |
2019-12-25 |
Urogen Pharma Ltd. |
BODY CAVES IMMUNODULATING TREATMENTS
|
|
US12274745B2
(en)
|
2016-10-28 |
2025-04-15 |
Toray Industries, Inc. |
Conjugate of CAPRIN-1 antibody linked to immune activator for cancer treatment
|
|
KR20220147720A
(ko)
|
2016-11-14 |
2022-11-03 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
|
JP2020511501A
(ja)
|
2016-12-13 |
2020-04-16 |
ボルト バイオセラピューティクス、インコーポレーテッド |
抗体アジュバント複合体
|
|
JP2020500264A
(ja)
|
2016-12-15 |
2020-01-09 |
アーコニック インコーポレイテッドＡｒｃｏｎｉｃ Ｉｎｃ． |
耐食性アルミニウム合金
|
|
CN110366564B
(zh)
|
2016-12-23 |
2023-07-07 |
瑞美德生物医药科技有限公司 |
使用与程序性死亡1(pd-1)结合的抗体的免疫疗法
|
|
WO2018119475A1
(en)
|
2016-12-23 |
2018-06-28 |
Remd Biotherapeutics, Inc. |
Immunotherapy using antibodies that bind programmed death ligand-1 (pd-l1)
|
|
JP7250679B2
(ja)
|
2017-01-10 |
2023-04-03 |
ネクター セラピューティクス |
Ｔｌｒ作動薬化合物のマルチアームポリマーコンジュゲート及び関連の免疫療法治療の方法
|
|
CA3049791A1
(en)
|
2017-01-27 |
2018-08-02 |
Silverback Therapeutics, Inc. |
Tumor targeting conjugates and methods of use thereof
|
|
CA3049842A1
(en)
|
2017-02-02 |
2018-08-09 |
Silverback Therapeutics, Inc. |
Construct-peptide compositions and methods of use thereof
|
|
TWI674261B
(zh)
|
2017-02-17 |
2019-10-11 |
美商英能腫瘤免疫股份有限公司 |
Nlrp3 調節劑
|
|
US20190374650A1
(en)
|
2017-02-22 |
2019-12-12 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of polymer/biomacromolecule conjugates
|
|
UA129583C2
(uk)
|
2017-03-06 |
2025-06-11 |
Мерк Патент Гмбх |
Водний фармацевтичний склад, який містить антитіло проти pd-l1 авелумаб
|
|
SG10202110183VA
(en)
|
2017-03-15 |
2021-10-28 |
Silverback Therapeutics Inc |
Benzazepine compounds, conjugates, and uses thereof
|
|
IL269328B2
(en)
|
2017-03-16 |
2023-11-01 |
Immunwork Inc |
Binding units and molecules containing them
|
|
WO2018175854A1
(en)
|
2017-03-23 |
2018-09-27 |
The Children's Medical Center Corporation |
Methods and compositions relating to adjuvants
|
|
EP3601368A4
(en)
|
2017-03-31 |
2021-03-31 |
Zymeworks Inc. |
TUMOR ANTIGEN PRESENTATION INDUCER CONSTRUCTIONS AND THEIR USES
|
|
AU2018250226B2
(en)
|
2017-04-04 |
2025-04-24 |
Barinthus Biotherapeutics North America, Inc. |
Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
|
|
MX2019011957A
(es)
|
2017-04-06 |
2019-11-07 |
Hangzhou Dac Biotech Co Ltd |
Conjugacion de un farmaco citotoxico con enlace bis.
|
|
US20180296685A1
(en)
|
2017-04-13 |
2018-10-18 |
Tarveda Therapeutics, Inc. |
Targeted constructs and formulations thereof
|
|
WO2018191746A1
(en)
*
|
2017-04-14 |
2018-10-18 |
Bolt Biotherapeutics, Inc. |
Immunoconjugate synthesis method
|
|
CA3058944A1
(en)
|
2017-04-19 |
2018-10-25 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
CN118515666A
(zh)
|
2017-04-27 |
2024-08-20 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
|
WO2018218215A1
(en)
|
2017-05-26 |
2018-11-29 |
The Johns Hopkins University |
Multifunctional antibody-ligand traps to modulate immune tolerance
|
|
CA3065919A1
(en)
|
2017-06-07 |
2018-12-13 |
Silverback Therapeutics, Inc. |
Antibody construct conjugates
|
|
WO2018227018A1
(en)
|
2017-06-07 |
2018-12-13 |
Silverback Therapeutics, Inc. |
Antibody conjugates of immune-modulatory compounds and uses thereof
|
|
US11517567B2
(en)
|
2017-06-23 |
2022-12-06 |
Birdie Biopharmaceuticals, Inc. |
Pharmaceutical compositions
|
|
CN111032087A
(zh)
|
2017-06-28 |
2020-04-17 |
小利兰·斯坦福大学托管委员会 |
用于dectin-2刺激和癌症免疫治疗的方法和组合物
|
|
WO2019023622A1
(en)
|
2017-07-27 |
2019-01-31 |
The Board Of Trustees Of The Leland Stanford Junior University |
POLYMERIC NANOPARTICLES FOR IMPROVED ANTICANCERIC IMMUNOTHERAPY
|
|
US10472361B2
(en)
|
2017-08-16 |
2019-11-12 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
|
|
US10457681B2
(en)
|
2017-08-16 |
2019-10-29 |
Bristol_Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
|
|
US10487084B2
(en)
|
2017-08-16 |
2019-11-26 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
|
|
US10494370B2
(en)
|
2017-08-16 |
2019-12-03 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
|
|
US10508115B2
(en)
|
2017-08-16 |
2019-12-17 |
Bristol-Myers Squibb Company |
Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
|
|
WO2019036031A2
(en)
|
2017-08-17 |
2019-02-21 |
Nektar Therapeutics |
IMMUNOTHERAPEUTIC METHOD FOR TUMOR TREATMENT
|
|
WO2019073080A1
(en)
|
2017-10-13 |
2019-04-18 |
Ose Immunotherapeutics |
ANTI-SIRPA MODIFIED ANTIBODIES AND USES THEREOF
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
US10722591B2
(en)
|
2017-11-14 |
2020-07-28 |
Dynavax Technologies Corporation |
Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
|
|
JP2021506827A
(ja)
|
2017-12-15 |
2021-02-22 |
シルバーバック セラピューティックス インコーポレイテッド |
肝炎の治療用の抗体コンストラクト−薬物コンジュゲート
|
|
US11866466B2
(en)
|
2017-12-19 |
2024-01-09 |
Blaze Bioscience, Inc. |
Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
|
|
KR20210006338A
(ko)
|
2018-03-13 |
2021-01-18 |
오제 이뮈노테라프틱스 |
항-인간 SIRPa v1 항체의 이용 및 항-SIRPa v1 항체를 생산하는 방법
|
|
US20210009711A1
(en)
|
2018-03-14 |
2021-01-14 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
WO2019195278A1
(en)
|
2018-04-02 |
2019-10-10 |
Silverback Therapeutics, Inc. |
Alk5 inhibitors, conjugates, and uses thereof
|
|
CN115192726A
(zh)
|
2018-04-03 |
2022-10-18 |
深圳大学 |
免疫激动剂靶向化合物的合成及其应用
|
|
WO2019209811A1
(en)
|
2018-04-24 |
2019-10-31 |
Bristol-Myers Squibb Company |
Macrocyclic toll-like receptor 7 (tlr7) agonists
|
|
CN112153988A
(zh)
|
2018-05-17 |
2020-12-29 |
博尔特生物治疗药物有限公司 |
免疫缀合物
|
|
WO2019236567A2
(en)
|
2018-06-04 |
2019-12-12 |
Trustees Of Tufts College |
Tumor microenvironment-activated drug-binder conjugated, and uses related thereto
|
|
AU2019304175A1
(en)
|
2018-07-09 |
2021-03-04 |
Genequantum Healthcare (Suzhou) Co., Ltd. |
Antibodies specific to trophoblast antigen 2 (TROP2)
|
|
US20210213010A1
(en)
|
2018-07-24 |
2021-07-15 |
Torque Therapeutics, Inc. |
Tlr7/8 agonists and liposome compositions
|
|
US11554120B2
(en)
|
2018-08-03 |
2023-01-17 |
Bristol-Myers Squibb Company |
1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
|
|
JP2022513306A
(ja)
|
2018-08-29 |
2022-02-07 |
ボルト バイオセラピューティクス、インコーポレーテッド |
Ｅｇｆｒを標的とする免疫結合体
|
|
EP3846807B1
(en)
|
2018-09-07 |
2023-08-02 |
Birdie Biopharmaceuticals, Inc. |
Imidazoquinoline compounds and uses thereof
|
|
JP2022500404A
(ja)
|
2018-09-12 |
2022-01-04 |
シルバーバック セラピューティックス インコーポレイテッド |
置換ベンゾアゼピン化合物、そのコンジュゲートおよび使用
|
|
AU2019337652A1
(en)
|
2018-09-12 |
2021-03-18 |
Silverback Therapeutics, Inc. |
Antibody conjugates of toll-like receptor agonists
|
|
CA3111784A1
(en)
|
2018-09-12 |
2020-03-19 |
Silverback Therapeutics, Inc. |
Methods and compositions for the treatment of disease with immune stimulatory conjugates
|
|
WO2020056194A1
(en)
|
2018-09-12 |
2020-03-19 |
Silverback Therapeutics, Inc. |
Benzazepine compounds, conjugates, and uses thereof
|
|
US20230053449A1
(en)
|
2018-10-31 |
2023-02-23 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
|
EP3873938A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody conjugates comprising sting agonists
|
|
CN113453725A
(zh)
|
2018-11-30 |
2021-09-28 |
百时美施贵宝公司 |
包含含有谷氨酰胺的轻链c末端延伸的抗体、其缀合物以及方法和用途
|
|
CN113544155A
(zh)
|
2018-12-12 |
2021-10-22 |
百时美施贵宝公司 |
经修饰用于转谷氨酰胺酶缀合的抗体、其缀合物以及方法和用途
|
|
CN113613641A
(zh)
|
2018-12-26 |
2021-11-05 |
博笛生物科技有限公司 |
用于治疗癌症的免疫调节组合和方法
|
|
EP3906055A4
(en)
|
2019-01-04 |
2023-01-04 |
Trio Pharmaceuticals, Inc. |
MULTISPECIFIC PROTEIN MOLECULES AND THEIR USES
|
|
MX2021007706A
(es)
|
2019-01-04 |
2021-08-05 |
Ascendis Pharma Oncology Div A/S |
Conjugados de agonistas de receptor de reconocimiento de patron.
|
|
CN119455003A
(zh)
|
2019-02-12 |
2025-02-18 |
Ambrx公司 |
包含抗体-tlr激动剂缀合物的组合物、方法和用途
|
|
US20220226492A1
(en)
|
2019-03-15 |
2022-07-21 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates Targeting HER2
|
|
WO2020190760A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting cea
|
|
US20220175762A1
(en)
|
2019-03-15 |
2022-06-09 |
Birdie Biopharmaceuticals, Inc. |
Immune modulatory compositions and methods for treating cancers
|
|
JP2022525594A
(ja)
|
2019-03-15 |
2022-05-18 |
ボルト バイオセラピューティクス、インコーポレーテッド |
Ｈｅｒ２を標的とする免疫結合体
|
|
US20220226491A1
(en)
|
2019-03-15 |
2022-07-21 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates Targeting PD-L1
|
|
WO2020190762A1
(en)
|
2019-03-15 |
2020-09-24 |
Bolt Biotherapeutics, Inc. |
Macromolecule-supported tlr agonists
|
|
US20220169737A1
(en)
|
2019-04-05 |
2022-06-02 |
Dren Bio, Inc. |
Methods of depleting disease causing agents via antibody targeted phagocytosis
|
|
CN114206392A
(zh)
|
2019-06-10 |
2022-03-18 |
苏特罗生物制药公司 |
免疫调节剂抗体药物偶联物及其用途
|
|
JP7558205B2
(ja)
|
2019-06-13 |
2024-09-30 |
ボルト バイオセラピューティクス、インコーポレーテッド |
高分子支持アミノベンズアピン化合物
|
|
AU2020291014B2
(en)
|
2019-06-13 |
2025-06-05 |
Bolt Biotherapeutics, Inc. |
Aminobenzazepine compounds, immunoconjugates, and uses thereof
|
|
US20220259202A1
(en)
|
2019-06-17 |
2022-08-18 |
Sutro Biopharma, Inc. |
1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
|
|
EP3986474A1
(en)
|
2019-06-19 |
2022-04-27 |
Silverback Therapeutics, Inc. |
Anti-mesothelin antibodies and immunoconjugates thereof
|
|
CA3146661A1
(en)
|
2019-07-16 |
2021-01-21 |
Silverback Therapeutics, Inc. |
Alk5 inhibitors, conjugates, and uses thereof
|
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
|
US11155567B2
(en)
|
2019-08-02 |
2021-10-26 |
Mersana Therapeutics, Inc. |
Sting agonist compounds and methods of use
|
|
JP2022544543A
(ja)
|
2019-08-15 |
2022-10-19 |
シルバーバック セラピューティックス インコーポレイテッド |
ベンザゼピンコンジュゲートの製剤およびその使用
|
|
EP4025254A1
(en)
|
2019-09-03 |
2022-07-13 |
Bolt Biotherapeutics, Inc. |
Aminoquinoline compounds, immunoconjugates, and uses thereof
|
|
WO2021046347A1
(en)
|
2019-09-04 |
2021-03-11 |
Bolt Biotherapeutics, Inc. |
Immunoconjugate synthesis method
|
|
WO2021061867A1
(en)
|
2019-09-23 |
2021-04-01 |
Cytomx Therapeutics, Inc. |
Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
|
|
EP4038053A1
(en)
|
2019-09-30 |
2022-08-10 |
Bolt Biotherapeutics, Inc. |
Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
|
|
AU2020357806A1
(en)
|
2019-09-30 |
2022-05-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Knottin-immunostimulant conjugates and related compositions and methods
|
|
WO2021067644A1
(en)
|
2019-10-01 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
WO2021072203A1
(en)
|
2019-10-09 |
2021-04-15 |
Silverback Therapeutics, Inc. |
Tgfbetar1 inhibitor-asgr antibody conjugates and uses thereof
|
|
CA3155077A1
(en)
|
2019-10-25 |
2021-04-29 |
Romas Kudirka |
Thienoazepine immunoconjugates, and uses thereof
|
|
CN114828894A
(zh)
|
2019-10-25 |
2022-07-29 |
博尔特生物治疗药物有限公司 |
高分子支撑的噻吩并氮呯化合物及其用途
|
|
WO2021113679A1
(en)
|
2019-12-06 |
2021-06-10 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
|
US11702474B2
(en)
|
2019-12-17 |
2023-07-18 |
Pfizer Inc. |
Antibodies specific for CD47, PD-L1, and uses thereof
|
|
CN114901694A
(zh)
|
2019-12-31 |
2022-08-12 |
启德医药科技（苏州）有限公司 |
抗trop2抗体、抗体-药物缀合物及其应用
|
|
CN115175917A
(zh)
|
2019-12-31 |
2022-10-11 |
启德医药科技（苏州）有限公司 |
药物缀合物及其应用
|
|
WO2021150702A1
(en)
|
2020-01-21 |
2021-07-29 |
Bolt Biotherapeutics, Inc. |
Anti-pd-l1 antibodies
|
|
EP4093510A1
(en)
|
2020-01-21 |
2022-11-30 |
Bolt Biotherapeutics, Inc. |
Anti-pd-l1 antibodies
|
|
WO2021168274A1
(en)
|
2020-02-21 |
2021-08-26 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
|
AU2021226570A1
(en)
|
2020-02-25 |
2022-09-29 |
Bolt Biotherapeutics, Inc. |
Cancer treatment methods
|
|
WO2021202921A1
(en)
|
2020-04-01 |
2021-10-07 |
Altimmune Uk Limited |
Imidazoquinoline-type compounds and uses thereof
|
|
MX2022012621A
(es)
|
2020-04-10 |
2023-01-18 |
Seagen Inc |
Enlazadores de variantes de carga.
|
|
WO2021222894A1
(en)
|
2020-05-01 |
2021-11-04 |
Bolt Biotherapeutics, Inc. |
Anti-dectin-2 antibodies
|
|
WO2021226440A1
(en)
|
2020-05-08 |
2021-11-11 |
Bolt Biotherapeutics, Inc. |
Elastase-substrate, peptide linker immunoconjugates, and uses thereof
|